Article thumbnail

Regression of follicular lymphoma with Devil’s Claw: coincidence or causation?

By K.S. Wilson
Topics: Short Communication
Publisher: Multimed Inc.
OAI identifier: oai:pubmedcentral.nih.gov:2722058
Provided by: PubMed Central

Suggested articles

Citations

  1. 131I–Tositumomab therapy as initial treatment for follicular lymphoma.
  2. (2008). Available at: www.nlm.nih.gov/medlineplus/druginfo/natural/ patient-devilsclaw.html; cited
  3. (2004). Cyclooxygenase-2 (c o x -2) expression in lymphomas. Leuk Lymphoma
  4. Cyclooxygenase-2 (c o x -2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
  5. (2008). Harpagophytum [Web article]. San Francisco: Wikimedia Foundation, Inc.;
  6. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929.
  7. (2009). Home > Patient/Public Info > Complementary and Alternative Cancer Therapies > Essiac/Flor·Essence [Web article]. Vancouver: BC Cancer Agency; n.d. [Available at: www.bccancer.bc.ca/PPI/UnconventionalTherapies/ EssiacFlor%2aEssence.htm; cited February 1,
  8. Increased cyclooxygenase-2 (c o x -2): a potential role in the pathogenesis of lymphoma.
  9. (2008). National Institutes of Health, National Cancer Institute (n c i ). Cancer Topics > Complementary and Alternative Medicine > Specific Topics: Essiac/Flor·Essence [patient] > Essiac/Flor·Essence (p d q ): Patient Version [Web article]. Bethesda, MD: n c i ;
  10. (2008). National Library of Medicine (n l m ) and the National Institutes of Health, MedlinePlus. Cancer Alternative Therapies [Web article].
  11. No initial therapy for stage iii and iv non-Hodgkin’s lymphomas of favorable histologic types.
  12. on behalf of the British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
  13. (1997). on behalf of the Groupe d’Etude des Lymphomes de l’Adulte. Comparison in lowtumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires.
  14. Phase iii study of r-c v p compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
  15. Spontaneous regression in non-Hodgkin’s lymphoma: clinical and pathogenetic considerations. Am J Hematol 1989;31:138–41. Correspondence to: Kenneth Scott Wilson,
  16. Spontaneous regression in non-Hodgkin’s lymphoma.
  17. (1980). Spontaneous regression of non-Hodgkin’s lymphoma: a report of nine cases.
  18. The effect of cele- The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
  19. (1984). The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.
  20. (1991). The natural history of low grade non-Hodgkin’s lymphoma and the impact of a no initial treatment policy on survival.
  21. The prevalence of complementary/ alternative medicine in cancer. A systematic review.
  22. (1988). The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.